


## KADIAN® continues to help reduce costs for your patients in 2011

Thank you for your help in processing your patients' KADIAN® Co-Pay Assistance Cards that allow them to save up to \$50 toward their KADIAN® prescriptions. We are pleased to announce that this important cost-savings program will continue into 2011, even when co-pay cards state that they expire in December, 2010. These cards may be used despite the expiration date – please process them as you would if the card had no expiration date. The card with the expiration date and the new “no expiration” date card are pictured below – both are valid in 2011.



For any questions please call the Pharmacy Help Desk at 1-800-422-5604.

### IMPORTANT SAFETY INFORMATION

#### WARNING:

**KADIAN® contains morphine sulfate, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. KADIAN® can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing KADIAN® in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.**

**KADIAN® capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.**

**KADIAN® Capsules are NOT for use as a prn analgesic.**

**KADIAN® 100 mg and 200 mg Capsules ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. Ingestion of these capsules or of the pellets within the capsules may cause fatal respiratory depression when administered to patients not already tolerant to high doses of opioids.**

**KADIAN® CAPSULES ARE TO BE SWALLOWED WHOLE OR THE CONTENTS OF THE CAPSULES SPRINKLED ON APPLE SAUCE. THE PELLETS IN THE CAPSULES ARE NOT TO BE CHEWED, CRUSHED, OR DISSOLVED DUE TO THE RISK OF RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF MORPHINE.**

KADIAN® is contraindicated in patients with a known hypersensitivity to morphine, morphine salts or any of the capsule components, or in any situation where opioids are contraindicated. This includes in patients with respiratory depression (in the absence of resuscitative equipment or in unmonitored settings), and in patients with acute or severe bronchial asthma or hypercarbia.

KADIAN® is contraindicated in any patient who has or is suspected of having paralytic ileus.

The most serious adverse events associated with KADIAN® and other opioid analgesics are respiratory depression, respiratory arrest, apnea, circulatory depression, cardiac arrest, hypotension, and/or shock.

The most frequent adverse events are drowsiness, dizziness, constipation, and nausea.

**Please click here to go to [www.kadian.com](http://www.kadian.com) for Full Prescribing Information, including Boxed Warning and other Important Safety Information.**

KADI1018

December 2010